S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
CVE:RX

BioSyent Price Target, Predictions & Analyst Ratings

C$7.25
+0.05 (+0.69 %)
(As of 09/23/2021 05:41 PM ET)
Add
Compare
Today's Range
C$6.95
C$7.25
50-Day Range
C$7.20
C$8.30
52-Week Range
C$6.59
C$9.59
Volume9,847 shs
Average Volume7,156 shs
Market CapitalizationC$91.81 million
P/E Ratio21.64
Dividend YieldN/A
BetaN/A

BioSyent (CVE:RX) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Hold
Based on 2 Analyst Ratings

Analyst Price Target Consensus

C$7.50

High PTC$7.50
Average PTC$7.50
Low PTC$7.50
TypeCurrent
9/27/20 to 9/27/21
1 Month Ago
8/28/20 to 8/28/21
3 Months Ago
6/29/20 to 6/29/21
1 Year Ago
9/28/19 to 9/27/20
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetC$7.50C$7.50C$7.50C$6.00
Price Target Upside3.45% Upside-2.60% Downside-1.96% Downside-11.37% Downside
Get BioSyent Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RX and its competitors with MarketBeat's FREE daily newsletter.


Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

BioSyent (CVE:RX) vs. Its Competitors

TypeBioSyentMedical Companies
Consensus Rating Score
2.00
2.72
Consensus RatingHoldBuy
News Sentiment RatingNeutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
92
66.67%
Underperform Votes
46
33.33%
Avg. Outperform Votes
177
67.30%
Avg. Underperform Votes
86
32.70%

BioSyent (CVE:RX) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/26/2021Raymond James
Set Price TargetMarket PerformC$7.50-2.60%
3/18/2021Bloom Burton
D. Martin
DowngradeAccumulate ➝ Hold
8/26/2019Cormark
Lower Price TargetC$8.25 ➝ C$7.50+25.00%
(Data available from 9/27/2016 forward. View 10+ years of historical ratings with our analyst ratings screener.)
speech bubbles
speech bubbles











BioSyent (CVE:RX) Analyst Ratings Frequently Asked Questions

What is BioSyent's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for BioSyent stock is Hold based on the current 2 hold ratings for RX. The average twelve-month price target for BioSyent is C$7.50 with a high price target of C$7.50 and a low price target of C$7.50. Learn more on RX's analyst rating history

Do Wall Street analysts like BioSyent more than its competitors?

Analysts like BioSyent stock less than the stock of other Medical companies. The consensus rating for BioSyent is Hold while the average consensus rating for medical companies is Buy. Learn more on how RX compares to other companies

Do MarketBeat users like BioSyent more than its competitors?

MarketBeat users like BioSyent stock less than the stock of other Medical companies. 66.67% of MarketBeat users gave BioSyent an outperform vote while medical companies recieve an average of 67.30% outperform votes by MarketBeat users.

Does BioSyent's stock price have much downside?

According to analysts, BioSyent's stock has a predicted downside of -2.60% based on their 12-month price targets.

What analysts cover BioSyent?

BioSyent has been rated by Raymond James in the past 90 days.

This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.